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OBJECTIVE: The primary endpoint was to analyze the predictive factors of lymph
node involvement (LN+).
BACKGROUND: Indications for additional right hemicolectomy (RHC) with lymph
node (LN) resection after appendectomy for appendix neuroendocrine tumor (A-NET)
remain controversial, especially for tumors between 1 and 2 cm in size.
METHODS: National study including all patients with nonmetastatic A-NET diagnosed
after January, 2010 in France.
RESULTS: In all, 403 patients were included. A-NETs were: within tip (67%), body
(24%) or base (9%) of the appendix; tumor size was < 1 cm (62%), 1 to 2 cm (30%), or
>2 cm (8%); grade 1 (91%); mesoappendix involvement 3 mm (5%); lymphovascular
(15%) or perineural (24%) invasion; and positive resection margin (8%). According to
the European NeuroEndocrine Tumor Society (ENETS) recommendations, 85 patients
(21%) should have undergone RHC. The agreement between ENETS guidelines and
the multidisciplinary tumor board for complementary RHC was 89%. In all, 100 (25%)
patients underwent RHC with LN resection, 26 of whom had LN+. Tumor size (best
cut-off at 1.95 cm), lymphovascular and perineural invasion, and pT classifications
were associated with LN+. Among the 44 patients who underwent RHC for a tumor of
1 to 2 cm in size, 8 (18%) had LN+. No predictive factor of LN+ (base, resection
margins, grade, mesoappendix, lymphovascular, perineural involvement) was found in
this subgroup of patients.
CONCLUSIONS: In the largest study using the latest pathological criteria for
completion RHC in A-NET, a quarter of patients had residual tumor. Further studies
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